Work

A phase 2 study of alisertib (MLN8237) in recurrent or persistent uterine leiomyosarcoma: An NRG Oncology/Gynecologic Oncology Group study 0231D

Year: 2016

Type: article

Study design: Clinical Trial

Source: Gynecologic Oncology

DOI: 10.1016/j.ygyno.2016.10.036

Authors: David M Hyman, Michael W Sill, Heather A Lankes, Richard Piekarz, Mark S Shahin, Mildred R Ridgway, Floor Backes, Meaghen E Tenney, Cara A. Mathews, James S Hoffman, Carol Aghajanian, Martee L Hensley

Institutions: Memorial Sloan Kettering Cancer Center, NRG Oncology, National Institutes of Health, National Cancer Institute, Abington Memorial Hospital, University of Mississippi Medical Center, The Ohio State University Wexner Medical Center, The Ohio State University, University of Chicago, Women & Infants Hospital of Rhode Island, The Hospital of Central Connecticut, Weill Cornell Medicine

Language: English

Topic: Uterine Myomas and Treatments

Subfield: Obstetrics and Gynecology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funders: National Institutes of Health, National Cancer Institute

Awards: G1291646684, NRG Oncology Network Group Operations Center, G467764903, Cancer Center Support Grant, NRG Oncology - Statistical and Data Management Center

OpenAlex ID: W2545879467

FWCI: 3.425

Cites: 37

Cited by: 22

Related to: 10